HONG KONG – Sanofi Pasteur Ltd. is taking a stand for itself amid a controversy that has quickly become a legal battle. The Public Attorney's Office of the Philippines (PAO) is taking legal action against Sanofi over the controversy surrounding the dengue vaccine Dengvaxia. And, the Filipino government agency recently filed a lawsuit against the French pharma company to demand compensation of up to PHP4.2 million (US$81,164) for the parents of Anjielica Pestilos, a 10-year-old girl the agency claims had died as a result of receiving its dengue vaccine.
HONG KONG – Sanofi Pasteur Ltd. is taking a stand for itself amid a controversy that has quickly become a legal battle. The Public Attorney's Office of the Philippines (PAO) is taking legal action against Sanofi over the controversy surrounding the dengue vaccine Dengvaxia.
HONG KONG – Astrazeneca plc has received approval for two drug candidates – PARP inhibitor Lynparza (olaparib) and IL-5 receptor targeting Fasenra (benralizumab) – from the Japanese Ministry of Health, Labour and Welfare, the latest sign of the big pharma's recent improvement in productivity following its 2011 overhaul.
HONG KONG – Less than two months after picking up a big win with the FDA approval for Mylan NV-partnered Herceptin biosimilar Ogivri (trastuzumab-dkst), India's Biocon Ltd. inked a deal with another leader in biosimilar development, Sandoz Inc., a division of Novartis AG, to develop, manufacture and commercialize multiple products in the areas of immunology and oncology.
HONG KONG – Astrazeneca plc has received approval for two drug candidates – PARP inhibitor Lynparza (olaparib) and IL-5 receptor targeting Fasenra (benralizumab) – from the Japanese Ministry of Health, Labour and Welfare, the latest sign of the big pharma's recent improvement in productivity following its 2011 overhaul.
HONG KONG – Singapore isn't just becoming a biotech hub. The island nation's biotech ecosystem is at "an inflection point," said Benjamin Seet, executive director of the biomedical research council at A*STAR (The Agency for Science, Technology and Research), a statutory board under the Ministry of Trade and Industry.
HONG KONG – Amoy Diagnostics Co. Ltd. (Amoydx) received CFDA approval for its epidermal growth factor receptor (EGFR) mutation detection kit as a companion diagnostic for EGFR TKI (tyrosine kinase inhibitor)-based non-small-cell lung cancer (NSCLC) drugs.
